Publicacions en què col·labora amb Nuria Romero Laorden (2)

2021

  1. Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (Mcrpc) patients

    Cancers, Vol. 13, Núm. 10

2018

  1. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)

    British Journal of Cancer, Vol. 119, Núm. 9, pp. 1052-1059